The evolution of mendelian randomization for investigating drug effects.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 35113864.
- Also identified by DOI 10.1371/journal.pmed.1003898 and PMC identifier 8812877.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Dipender Gill and Stephen Burgess discuss the accompanying study by James Yarmolinsky and colleagues investigating the associations between genetically-proxied inhibition of antihypertensive drug targets and risk of common cancer subtypes using Mendelian randomization.
Medical subject headings
- Angiotensin-Converting Enzyme Inhibitors
- Antihypertensive Agents
- Colorectal Neoplasms
- Genome-Wide Association Study
- Mendelian Randomization Analysis